IndustryAssistance
Pharmaceutical Industry Involvement
Fabry Australia attracts attention from the pharmaceutical companies that have an interest in the development of treatments and other services for Fabry disease patients. Fabry Australia welcomes financial support from the pharmaceutical indsutry and other commercial companies providing the relationship is based on the following principles:
- relevance of a public health objective
- driven by patient needs
- full independence of Fabry Australia
- mutual respect
- mutual benefit
- accountability and transparency
Fabry Australia believes it is important to establish and maintain relationships with the pharmaceutical industry to enhance communication between Fabry disease patients, whose interests Fabry Australia represents and companies, whose decisions will affect provision of health services or treatments to Fabry disease patients.
Fabry Australia currently receives educational grants from the following companies:
Amicus Therapeutics
Sanofi
Takeda
4DMT
As a member of Medicines Australia all pharmaceutical companies are bound by its code of conduct. The code sets out standards of conduct for the activities and agreements for companies to engage in with patient associations as permitted by Australian legislation. Fabry Australia makes it clear that the association does not place any obligation (legal or otherwise) on the companies that provide educational grants to Fabry Australia Inc. in relation to the companies, their brand and their products. To understand and read more visit Medicines Australia Code of Conduct
